GanglioneuroblastomaSymptoms, Doctors, Treatments, Advances & More
Learn About Ganglioneuroblastoma
View Main Condition: Neuroblastoma
Ganglioneuroblastoma is an intermediate tumor that arises from nerve tissues. An intermediate tumor is one that is between benign (slow-growing and unlikely to spread) and malignant (fast-growing, aggressive, and more likely to spread).
Ganglioneuroblastoma mostly occurs in children ages 2 to 4 years. The tumor affects boys and girls equally. It occurs rarely in adults. Tumors of the nervous system have different degrees of differentiation. This is based on how the tumor cells look under the microscope. It can predict whether or not they are likely to spread.
Benign tumors are less likely to spread. Malignant tumors are aggressive, grow quickly, and often spread. A ganglioneuroma is less malignant in nature. A neuroblastoma (occurring in children over 1 year old) is usually malignant.
A ganglioneuroblastoma may be only in one area or it may be widespread, but it is usually less aggressive than a neuroblastoma. The cause is unknown.
Most commonly, a lump can be felt in the abdomen with tenderness.
This tumor may also occur at other sites, including:
- Chest cavity
- Neck
- Legs
Depending on the type of tumor, treatment can involve surgery, and possibly chemotherapy and radiation therapy.
Because these tumors are rare, they should be treated in a specialized center by experts who have experience with them.
Rockefeller Outpatient Pavilion
Mark Dickson is an Oncologist practicing medicine in New York, New York. Dr. Dickson is rated as a Distinguished provider by MediFind in the treatment of Ganglioneuroblastoma. He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Undifferentiated Pleomorphic Sarcoma, Synovial Sarcoma, and Endoscopy. Dr. Dickson is currently accepting new patients.
Office
Frederick Eilber is a General Surgeon practicing medicine in Los Angeles, California. Dr. Eilber is rated as a Distinguished provider by MediFind in the treatment of Ganglioneuroblastoma. He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Synovial Sarcoma, Retroperitoneal Liposarcoma, and Liposarcoma.
Duke Cancer Center
Richard Riedel is an Oncologist practicing medicine in Durham, North Carolina. Dr. Riedel is rated as a Distinguished provider by MediFind in the treatment of Ganglioneuroblastoma. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Desmoid Tumor, and Angiosarcoma. Dr. Riedel is board certified in American Board Of Internal Med, Internal Medicine and American Board Of Internal Med, Medical Oncology. Dr. Riedel is currently accepting new patients.
More information and support for children with ganglioneuroblastoma and their families can be found at:
- Children's Oncology Group -- www.childrensoncologygroup.org
- The Neuroblastoma Children's Cancer Society -- neuroblastomachildrenscancersociety.org/
The outlook depends on how far the tumor has spread, and whether some areas of the tumor contain more aggressive cancer cells.
Complications that may result include:
- Complications of surgery, radiation, or chemotherapy
- Spread of the tumor into surrounding areas
Contact your provider if you feel a lump or growth on your child's body. Make sure children receive routine exams as part of their well-child care.
Summary: This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neur...
Summary: This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Gi...
Published Date: October 21, 2025
Published By: Warren Brenner, MD, Oncologist, Lynn Cancer Institute, Boca Raton, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Dorsey JF, Salinas RD, Dang M, et al. Cancer of the central nervous system. In: Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE, eds. Abeloff's Clinical Oncology. 6th ed. Philadelphia, PA: Elsevier; 2020:chap 63.
Hernandez Tejada FN, Harrison DJ. Neuroblastoma. In: Kliegman RM, St. Geme JW, Blum NJ, et al, eds. Nelson Textbook of Pediatrics. 22nd ed. Philadelphia, PA: Elsevier; 2025:chap 547.
National Cancer Institute website. Neuroblastoma treatment (PDQ) - health professional version. www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq. Updated April 28, 2025. Accessed December 14, 2025.